Optina Diagnostics (Canada)
We combine our FDA 510(k) cleared hyperspectral camera with leading AI capabilities to enable eye specialists to more accurately diagnose and manage early, intermediate and late-stage retinal disease, including monitoring therapeutic effectiveness in at-risk patients. We believe the devastating health impacts of AMD can be significantly reduced, and even prevented, with a better approach to early-stage detection and risk monitoring Retinal imaging and AI platform that supports faster and more ef
Basic Information
- Category: business
- Website: http://www.optinadx.com/
Documented Facts
- Inception (Wikidata): 2011 (Source 2: Wikidata Q30267298, revision 2474198324)
- Country (Wikidata; date unspecified): Canada (Source 2: Wikidata Q30267298, revision 2474198324; Source 3: Wikidata label: Q16, revision 2555105353)
- Official website (Wikidata; date unspecified): http://www.optinadx.com/ (Source 2: Wikidata Q30267298, revision 2474198324)
Evidence and Sources
- Optina Diagnostics (Canada) — Official Website (official)
- Wikidata Q30267298, revision 2474198324 (knowledge-base)
- Wikidata label: Q16, revision 2555105353 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Optina Diagnostics (Canada).
- Canonical profile: https://brandsource.ai/brands/optina-diagnostics-canada
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/optina-diagnostics-canada/json-ld
- Citation profile API: https://brandsource.ai/api/brands/optina-diagnostics-canada/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (91/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We combine our FDA 510(k) cleared hyperspectral camera with leading AI capabilities to enable eye specialists to more accurately diagnose and manage early, intermediate and late-stage retinal disease, including monitoring therapeutic effectiveness in at-risk patients. We believe the devastating health impacts of AMD can be significantly reduced, and even prevented, with a better approach to early-stage detection and risk monitoring Retinal imaging and AI platform that supports faster and more ef
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 3 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.